Meeting Banner
Abstract #0824

MR-HIFU mild hyperthermia for sensitization of radiation and chemotherapy for recurrent rectal cancer: First phase I clinical trial results.

William Chu1, Robert Staruch2, Samuel Pichardo3,4, Yuexi Huang5, Charles Mougenot6, Matti Tillander7, Max O. Köhler7, Mika Ylihautala7, Merrylee McGuffin1, Gregory Czarnota1, and Kullervo Hynynen5

1Radiation Oncology, Sunnybrook Health Science Centre, Toronto, ON, Canada, 2Philips Research, Cambridge, MA, United States, 3Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada, 4Electrical Engineering, Lakehead University, Thunder Bay, ON, Canada, 5Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, 6Philips Healthcare, Toronto, ON, Canada, 7Philips Healthcare, Vantaa, Finland

We present the first results of a Phase I trial that includes delivery of mild hyperthermia using magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) combined with radiation and chemotherapy in the treatment of locally recurrentrectal cancer. MR-HIFU mild hyperthermia was delivered in three sessions (day 1, 8 and 15) during a 17-day treatment protocol (total dose 30.6 Gy combined with fluropyrimidine-based chemotherapy). MR-HIFU mild hyperthermia was successfully delivered and the procedure was well tolerated by the patient. No adverse effects have been reported 3 months after the treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here